Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Generic: TR-700
TR-700 is an investigational broad-spectrum antiviral drug being developed by Tokyo Tatemono Co., Ltd. It is a capsid-binding inhibitor designed to target a broad range of enteroviruses, including poliovirus, rhinovirus, and enterovirus 71 (EV71), as well as other picornaviruses like foot-and-mouth disease virus. Its mechanism involves binding to the viral capsid, preventing the release of viral RNA and thus inhibiting viral replication.
TR-700 is being investigated for the treatment of enterovirus and picornavirus infections.
Most likely new formulation: Oral formulation for broader application in endemic areas (2026, 50% confidence)
Based on preclinical and early clinical data, there is a moderate likelihood of TR-700 progressing to later-stage clinical trials for specific enterovirus infections.
Antiviral Agent
Imidazolidinone derivative